Triple Negative Breast Cancer (TNBC), Early Setting research hub

Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.

This study, called CAPTIVATE, looks at how gut bacteria (microbiome) in women with early-stage triple-negative breast cancer affects their treatment with chemotherapy and immunotherapy. Researchers will collect samples to understand if gut bacteria influence how well treatments work.